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TABLE 1. NHP scores at t 1 and t2; t 1 is baseline score, t2 is second score, which was at 1 yr for 88 
patients, 2 yr for 50 patients and 3 yr for 13 patients (tl scores for the initial group are shown as well 
as for the patients who had follow-up studies performed) 
152 patients with follow-up 
All 204 patients 
W~~p,X~y :szd 
tl* tl* t2* P= 
Part 1 Energy 
Pain 
Emotion 
Sleep 
Social isolation 
Physical mobility 
CF_-specific total score 
Low scores=good quality of life 
(02024) 21 22 
a 24) (0, 24) 
(0.30) to3 0) co: 01 
(01:8) 
1; 
(0, 17) (Oslo) 
11 11 
(0, 13) (0, 13) (OP13) 
9 
(0, 0) to7 0) 
4 ; 
(0’ 0) 
ki 
(0, 0) (0. 0) (0, 17) 
4.4 4.7 
(2, 6) (2.4, 7) 
n.s. 
n.s. 
0.02 
n.s. 
n.s. 
n.s. 
0.008 
% with problems Chi-squared 
Part 2 Work 21 25 27 
Home (relationships) 23 25 28 
Social life 27 29 29 
Home life 10 9 10 
Sex life 14 16 19 
Hobbies 29 31 26 
Holidays 22 26 30 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
*The mean is followed, in parentheses, by the 25th percentile and the 75th percentile. 
n.s., not significant. 
sex, and norms for a healthy population have been 
published (6). In addition a short ‘in-house’ CF-specific 
questionnaire was administered (4). This questionnaire 
generates a score out of 15 based on time spent on 
physiotherapy and nebulizer treatment, time spent in 
hospital, amount of sputum produced, and degree of 
breathlessness. Spirometry was performed on a dry wedge 
spirometry by an experienced operator, and the FEV,% 
predicted, FVC% predicted (7) FEVJFVC ratio, and body 
mass index (BMI), were calculated. The patients were then 
studied at subsequent annual review appointments 
with repeat NHP, CF-specific questionnaire and repeat 
measurements of physiological parameters. 
Statistics 
Change in NHP scores and change in physiological par- 
ameters were calculated and expressed as unit change per 
year. Significance of change was assessed using the 
Wilcoxon matched pairs signed rank test as the data from 
the NHP are non-parametric. However, mean scores are 
also presented both to allow comparison with published 
data, and also because the median is often zero. A paired 
Student’s t-test was used to assess significance of change for 
the physiological data. Any relationship between change in 
NHP scores and change in physiological parameters was 
examined using Spearman’s Rank correlation coefficient. A 
P value of ~0.01 was taken to indicate clinical significance 
in view of the number of comparisons being made. Differ- 
ence between the group with rapid decline in FEV, and 
those with slow decline in FEV, was examined using a 
Mann-Whitney U test. 
Results 
Initial (tl) NHP scores were obtained from 204 patients 
whose median age was 26 years (range 1656 years). Mean 
(SD) FEV,% was 50 (24)% predicted, FVC 71 (24)% pre- 
dicted and FEV,/FVC was 59 (15)%. Mean (SD) BMI was 
20.4 (3.0) kg m-‘. Follow-up scores were obtained from 
152 (75% of the total) patients at an interval of 1, 2 or 3 yr. 
The follow-up study is represented by t2, whatever the time 
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TABLE 2. NHP scores at tl and t2 grouped according to time of follow-up study (tl is baseline score, t2 is follow-up score) 
Patients who had follow up at Patients who had follow up at 
1 yr (i.e. t2= 1 yr) (n=88) 2 yr (i.e. t2=2 yr) (n=50) 
t1 t2 tl t2 
Age 
FEV,% 
FVC% 
FEV,/FVC 
BMI (body mass index) 
NHP 
Energy 
Pain 
Emotion 
Sleep 
Social isolation 
Physical mobility 
27 (1646) 28 (17-47) 28 (1656) 29 (19-58) 
50 (23)% 50 (25)% 49 (22)% 50 (22)% 
72 (24)0X1 72 (26)% 73 (23)% 75 (22)% 
58 (13)% 58 (12)% 57 (12)% 56 (13)% 
20.6 (2.7) 20.6 (3.0) 20.4 (2.8) 20.5 (3.0) 
WSR WSR 
Mean (Ql, Q3)* P= P= 
20 (0, 24) 19 (0, 24) n.s. 24 (0, 39) 25 (0, 24) ns. 
3 (0, 0) 4 (0, 0) 0.04 4 (0, 0) 2 a 0) n.s. 
10 (0, 17) 7 (0, 10) 0.01 15 (0, 24) 11 (0, 17) 
8 (0, 13) 10 (0, 13) n.s. 17 (0, 34) 9 (0, 13) ::s)O6 
6 (0, 0) 6 (0, 0) n.s. 6 (0, 0) 7 (0, 0) ns. 
4 (0, 0) 6 (0, 11) n.s. 4 (0, 0) 7 (0, 11) ns. 
*Ql, 25th percentile; 43, 75th percentile; WSR, Wilcoxon Signed Rank test; ns., not significant. 
interval. The reasons for missing data were that six patients 
had died. four were now attending other centres, four had 
been transplanted, and 38 were missed at review. The 
physiology of the patients who had follow-up studies 
performed was not significantly different from the original 
group: age 26 (1656) years, FEV,% 50 (23)%, FVC 73 
(24)%, FEV,/FVC 58 (12)%, BMI 20.5 (2.8). Eighty-eight 
patients were re-studied at an interval of 1 yr, 50 at an 
interval of 2 yr and 13 at 3 yr after the first questionnaire. 
Mean (SD) rate of change in FEV, was - 8.6 (261) ml yr - ’ 
or - 0.2 (6,9)0X1 predicted yr - i. Mean rate of change in 
FVC was - 6.8 (449) ml yr - ‘, mean change in FEV,/FVC 
was - 0.7 (6.9)%. Mean rate of change in BMI was - 0.007 
(1.4)kgm-*yr-‘. 
Results of NHP scores at tl and t2 are shown in Table 1. 
The only dimension of the NHP which showed a significant 
overall change over time was emotion, which showed a 
small improvement in score (score at tlxl1.3, score at 
t2=8.1, P=O.O2). There was a statistically significant 
worsening of the ‘CF-specific’ total score from tl to t2 
(tl=4.4, t2=4.7, P=O.OOS). In Table 2 the patients are 
grouped according to whether their follow-up studies were 
performed at 1 yr or 2 yr (those at 3 yr are excluded from 
this table). This shows an improvement in emotion in the 
studies spaced at 1 yr but not in those spaced at 2 yr. There 
is a significant improvement in the sleep score shown in the 
studies taken at 2 yr, but this is not shown in the studies at 
1 yr. There is a slight worsening of the pain score seen in the 
studies spaced at 1 yr which is not seen in the studies spaced 
at 2 yr. 
Correlation between change in NHP scores and change in 
physiological parameters and change in symptoms is shown 
in Table 3. The only correlations between change in physi- 
ology and change in NHP score were ‘weak correlations 
between change in FVC and change in .the energy dimen- 
sion (r= - 0.19, P=O.O2) and change in FVC and change in 
social isolation (r=0.17, P=O.O4). Both of these P values 
are above the level that we were taking as indicative of 
clinical significance. However, there was a highly significant 
correlation between change in the CF-specific total score 
and change in energy (P=O.OOl) and physical mobility 
(P=O.O02) scores. 
Because the overall differences in FEV, between tl and t2 
was not marked, and in fact not statistically significant, the 
patients were divided in those who had a decline in FEV,% 
of greater than 4% per year (n=40) and those with a slower 
rate of decline (n= 112). There was no significant difference 
in change in NHP scores between the patients whose FEV, 
declined at >4% predicted yr - ’ and those who did not, as 
shown in Table 4. In addition, change in NHP scores 
grouped according to the patients’ initial FEV,% are shown 
in Table 5. The faster decline in FEV, is seen in the group 
with the best initial FEV, but there is no difference in 
change in HS scores across the groups. 
Discussion 
The Nottingham Health Profile has been shown both to 
correlate well with clinical status at one time point (4) and 
to detect a significant improvement in quality of life follow- 
ing heart-lung transplantation in CF (5). The present study 
showed no significant change at the P=O.Ol level in NHP 
scores over a l-2 yr period when patients were assessed at a 
stable phase of their disease. However, in this group of 
adults with CF the change in clinical status, as judged by 
change in FEV,, was not very great and it may be that 
changes in HS scores would be detected if the interval time 
were lengthened. Although the mean change in FEV, was 
not significant within the group, there were large changes in 
FEV, (from - 27 to +26% yr- ‘). It was for this reason 
that the patients were divided into fast and slow decliners 
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TABLE 3. Spearman’s rank correlation coefficients between change (‘d’) in NHP dimensions and change in physiological 
parameters and CF-specific scores. All change values calculated per year. Correlation coefficients are not given where not 
statistically significant at the PzO.05 level 
dBMI dFEV, dFVC dHosp dSputum dP+N dSOB dCF,o, 
dEnergy 
dPain 
dEmotion 
n.s. 
n.s. 
ns. 
n.s. 
ns. 
n.s. 
r= - 0.19, 
P=O.O2 
n.s. 
ns. 
dSleep 
dSocia1 isolation 
dPhysica1 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
n.s. 
rz0.17, 
P=O.O4 
n.s. 
n.s. 
n.s. 
rx0.2 
P=O.Oi 
n.s. 
n.s. 
r=0.16, 
P=O.O4 
rx0.18, 
P=O.O3 
n.s. 
ns. 
ns. 
n.s. 
n.s. 
rz0.17 
P=O.O4’ 
n.s. 
n.s. 
n.s. n.s. n.s. 
n.s. n.s. n.s. 
n.s. n.s. r=0.26, 
P= 0.002 
r=0.26 
P=O.OOi 
n.s. 
n.s. 
n.s. 
n.s. 
r=0.25, 
P=O.O02 
Spearman’s Rank Correlation Coefficient. 
dHosp, change in time spent in hospital; dSputum, change in sputum production; dP+N, change in time spent on nebulizer 
therapy plus physiotherapy; dSOB, change in breathlessness score; dCF,,,, change in CF-specific total score; n.s., not 
significant. 
TABLE 4. Change (‘d’) in NHP scores in patients with rapid decline in FEV, compared with change 
in NHP scores in those without rapid decline (all change values calculated per year) 
dSocia1 dPhysica1 
dEnergy dPain dEmotion dSleep isolation mobility 
dFEV, >4% - yr ’ 
(n=40) 
dFEV, <4% ~ yr ’ 
(n=112) 
Mann-Whitney U test, P= 
- 1.1 2 - 3.6 3.4 - 1.4 2.1 
2.2 0.3 - 2.5 - 3.4 - 0.5 1.4 
n.s. n.s. n.s. n.s. n.s. n.s. 
n.s., not significant. 
TABLE 5. Rate of change of NHP scores (per year) grouping patients according to their initial FEV,% 
predicted [values =mean (SD)] 
FEV,% ~40% FEV ,0/o 40&69% FEV,% >70% 
(n=61) (n=57) (n=34) ANOVA 
dFEV, ml yr - ’ 15 (261) - 3 (270) - 37 (250) ns. 
dEnergy 0.6 (27) - 1.1 (15) - 0.4 (24) n.s. 
dPain 2.3 (10) - 1.2 (8) 0.8 (4) n.s. 
dEmotion - 2.0 (14) - 4.0 (11) - 1.4 (8) n.s. 
dSleep - 1.7 (22) - 1.6 (13) 2.2 (11) n.s. 
dSocia1 isolation - 1.4 (11) - 1.0 (9) 1.1 (7) n.s. 
dPhysica1 mobility 2.6 (10) -0.1 (5) 1.1 (7) n.s. 
n.s., not significant. 
on the bases of their GFEV,. No greater change in scores 
was seen in patients with faster declining FEV,. In addition, 
no convincing correlation between change in HS scores and 
change in physiological parameters was detected. However, 
it should not be assumed that there would necessarily 
be a correlation between HS scores and physiological 
parameters, as perhaps these parameters are (or should be) 
measuring different things, i.e. change in HS may not be so 
dependent on change in physiological parameters. There 
was a significant correlation between change in the energy 
and physical mobility dimensions and change in the ‘CF- 
specific’ total score, which is primarily a symptom score. 
272 J. CONGLETON ET AL. 
The NHP may not be the best HS tool to use in this 
group of patients. We have noted previously that CF 
patients’ scores appeared to be skewed and that they score 
similarly to groups with minor conditions such as varicose 
veins and pregnancy at 18 weeks (4). This means that, for 
the NHP, CF patients tend to score a high number of zeros 
and this may make analysis difficult. There is not, as yet, a 
fully validated ‘CF-specific’ health status questionnaire, 
and it seems likely that this would provide more useful 
information than generic questionnaires. 
Conclusion 
We conclude that few significant changes in HS as 
measured by the NHP were detected over a 2 yr period in 
CF patients, and that it is worth exploring the performance 
of other HS questionnaires in this respect. This study 
supports the need for development of a fully validated 
‘CF-specific health status questionnaire’. 
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